Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Share-based Compensation: 2020-2024

Historic Share-based Compensation for Immuneering (IMRX) over the last 5 years, with Dec 2024 value amounting to $6.5 million.

  • Immuneering's Share-based Compensation rose 5.13% to $1.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was $6.5 million, marking a year-over-year increase of 13.52%. This contributed to the annual value of $6.5 million for FY2024, which is 13.52% up from last year.
  • Per Immuneering's latest filing, its Share-based Compensation stood at $6.5 million for FY2024, which was up 13.52% from $5.7 million recorded in FY2023.
  • Immuneering's 5-year Share-based Compensation high stood at $6.5 million for FY2024, and its period low was $1.1 million during FY2020.
  • Over the past 3 years, Immuneering's median Share-based Compensation value was $5.7 million (recorded in 2023), while the average stood at $5.4 million.
  • Data for Immuneering's Share-based Compensation shows a peak YoY soared of 125.47% (in 2022) over the last 5 years.
  • Over the past 5 years, Immuneering's Share-based Compensation (Yearly) stood at $1.1 million in 2020, then spiked by 65.87% to $1.8 million in 2021, then surged by 125.47% to $4.1 million in 2022, then spiked by 40.91% to $5.7 million in 2023, then grew by 13.52% to $6.5 million in 2024.